AAPL308.16-1.22 (-0.39%) ▼|ABBV245.74+1.94 (+0.80%) ▲|ABT104.64-0.82 (-0.78%) ▼|ACN170.16-0.27 (-0.16%) ▼|ADBE257.84+0.35 (+0.13%) ▲|AMAT539.78-6.84 (-1.25%) ▼|AMD487.12-31.46 (-6.07%) ▼|AMGN403.06+13.04 (+3.34%) ▲|AMT166.76-8.50 (-4.85%) ▼|AMZN271.15-6.27 (-2.26%) ▼|AVGO420.76+2.60 (+0.62%) ▲|AXP347.71+1.00 (+0.29%) ▲|BA239.28+2.12 (+0.89%) ▲|BAC63.45+0.55 (+0.87%) ▲|BKNG207.18+12.91 (+6.65%) ▲|BLK1,128.34-2.79 (-0.25%) ▼|BMY63.71-2.18 (-3.31%) ▼|BNY159.51+2.69 (+1.72%) ▲|BRK-B516.49-0.73 (-0.14%) ▼|C138.16+1.29 (+0.94%) ▲|CAT887.14+10.60 (+1.21%) ▲|CL93.29+0.76 (+0.82%) ▲|CMCSA24.59-0.35 (-1.38%) ▼|COF221.68-0.24 (-0.11%) ▼|COP116.15-1.79 (-1.52%) ▼|COST940.52-7.33 (-0.77%) ▼|CRM192.45+1.46 (+0.76%) ▲|CSCO122.96+1.22 (+1.00%) ▲|CVS99.72-4.70 (-4.50%) ▼|CVX187.33-3.07 (-1.61%) ▼|DE613.30-4.07 (-0.66%) ▼|DHR198.08+3.30 (+1.69%) ▲|DIS101.48+3.30 (+3.36%) ▲|DUK123.19-1.09 (-0.87%) ▼|EMR162.44+3.60 (+2.27%) ▲|FDX311.10-2.24 (-0.71%) ▼|GD382.85-2.91 (-0.75%) ▼|GE380.85+3.57 (+0.95%) ▲|GEV1,030.15+11.62 (+1.14%) ▲|GILD131.29-3.96 (-2.93%) ▼|GM89.11+0.80 (+0.91%) ▲|GOOG360.82-14.53 (-3.87%) ▼|GOOGL362.78-14.87 (-3.94%) ▼|GS1,073.67+20.69 (+1.97%) ▲|HD351.58+3.34 (+0.96%) ▲|HON248.44-0.36 (-0.14%) ▼|IBM237.14+1.99 (+0.85%) ▲|INTC102.23+1.37 (+1.36%) ▲|INTU325.37+1.77 (+0.55%) ▲|ISRG374.72+6.46 (+1.75%) ▲|JNJ258.38+3.45 (+1.35%) ▲|JPM360.55+3.03 (+0.85%) ▲|KO86.76+0.20 (+0.23%) ▲|LIN491.60+6.96 (+1.44%) ▲|LLY1,159.61+43.93 (+3.94%) ▲|LMT580.35-8.99 (-1.52%) ▼|LOW219.14+1.06 (+0.49%) ▲|LRCX312.17-5.57 (-1.75%) ▼|MA571.41+0.31 (+0.05%) ▲|MCD272.64+4.30 (+1.60%) ▲|MDLZ62.53+0.45 (+0.72%) ▲|MDT85.59-0.61 (-0.71%) ▼|META582.87-5.07 (-0.86%) ▼|MMM182.79+1.34 (+0.74%) ▲|MO68.15+0.08 (+0.11%) ▲|MRK128.69+0.69 (+0.54%) ▲|MS219.17+2.13 (+0.98%) ▲|MSFT489.21-3.60 (-0.73%) ▼|MU918.35+25.68 (+2.88%) ▲|NEE85.84-1.36 (-1.56%) ▼|NFLX73.46-0.11 (-0.15%) ▼|NKE42.03+0.50 (+1.21%) ▲|NOW116.90-1.25 (-1.05%) ▼|NVDA221.60+9.66 (+4.56%) ▲|ORCL144.20-1.54 (-1.06%) ▼|PEP138.62-0.48 (-0.35%) ▼|PFE25.55+0.14 (+0.55%) ▲|PG146.69-1.32 (-0.89%) ▼|PLTR159.42-3.24 (-1.99%) ▼|PM189.38+2.47 (+1.32%) ▲|QCOM157.84-4.83 (-2.97%) ▼|RTX221.68+3.75 (+1.72%) ▲|SBUX105.61+0.64 (+0.61%) ▲|SCHW108.27+1.92 (+1.81%) ▲|SO92.78-0.47 (-0.50%) ▼|SPG225.22-0.68 (-0.30%) ▼|T22.88-0.50 (-2.14%) ▼|TMO575.72+10.97 (+1.94%) ▲|TMUS172.75-4.46 (-2.52%) ▼|TSLA321.03-6.32 (-1.93%) ▼|TXN278.38-5.26 (-1.85%) ▼|UBER67.38-4.62 (-6.41%) ▼|UNH415.81+8.26 (+2.03%) ▲|UNP294.69-1.66 (-0.56%) ▼|UPS107.91-1.21 (-1.10%) ▼|USB64.42+0.19 (+0.30%) ▲|V368.86-0.73 (-0.20%) ▼|VZ45.79-1.10 (-2.34%) ▼|WFC89.26+0.87 (+0.98%) ▲|WMT111.67+0.12 (+0.11%) ▲|XOM152.18-1.78 (-1.16%) ▼|AAPL308.16-1.22 (-0.39%) ▼|ABBV245.74+1.94 (+0.80%) ▲|ABT104.64-0.82 (-0.78%) ▼|ACN170.16-0.27 (-0.16%) ▼|ADBE257.84+0.35 (+0.13%) ▲|AMAT539.78-6.84 (-1.25%) ▼|AMD487.12-31.46 (-6.07%) ▼|AMGN403.06+13.04 (+3.34%) ▲|AMT166.76-8.50 (-4.85%) ▼|AMZN271.15-6.27 (-2.26%) ▼|AVGO420.76+2.60 (+0.62%) ▲|AXP347.71+1.00 (+0.29%) ▲|BA239.28+2.12 (+0.89%) ▲|BAC63.45+0.55 (+0.87%) ▲|BKNG207.18+12.91 (+6.65%) ▲|BLK1,128.34-2.79 (-0.25%) ▼|BMY63.71-2.18 (-3.31%) ▼|BNY159.51+2.69 (+1.72%) ▲|BRK-B516.49-0.73 (-0.14%) ▼|C138.16+1.29 (+0.94%) ▲|CAT887.14+10.60 (+1.21%) ▲|CL93.29+0.76 (+0.82%) ▲|CMCSA24.59-0.35 (-1.38%) ▼|COF221.68-0.24 (-0.11%) ▼|COP116.15-1.79 (-1.52%) ▼|COST940.52-7.33 (-0.77%) ▼|CRM192.45+1.46 (+0.76%) ▲|CSCO122.96+1.22 (+1.00%) ▲|CVS99.72-4.70 (-4.50%) ▼|CVX187.33-3.07 (-1.61%) ▼|DE613.30-4.07 (-0.66%) ▼|DHR198.08+3.30 (+1.69%) ▲|DIS101.48+3.30 (+3.36%) ▲|DUK123.19-1.09 (-0.87%) ▼|EMR162.44+3.60 (+2.27%) ▲|FDX311.10-2.24 (-0.71%) ▼|GD382.85-2.91 (-0.75%) ▼|GE380.85+3.57 (+0.95%) ▲|GEV1,030.15+11.62 (+1.14%) ▲|GILD131.29-3.96 (-2.93%) ▼|GM89.11+0.80 (+0.91%) ▲|GOOG360.82-14.53 (-3.87%) ▼|GOOGL362.78-14.87 (-3.94%) ▼|GS1,073.67+20.69 (+1.97%) ▲|HD351.58+3.34 (+0.96%) ▲|HON248.44-0.36 (-0.14%) ▼|IBM237.14+1.99 (+0.85%) ▲|INTC102.23+1.37 (+1.36%) ▲|INTU325.37+1.77 (+0.55%) ▲|ISRG374.72+6.46 (+1.75%) ▲|JNJ258.38+3.45 (+1.35%) ▲|JPM360.55+3.03 (+0.85%) ▲|KO86.76+0.20 (+0.23%) ▲|LIN491.60+6.96 (+1.44%) ▲|LLY1,159.61+43.93 (+3.94%) ▲|LMT580.35-8.99 (-1.52%) ▼|LOW219.14+1.06 (+0.49%) ▲|LRCX312.17-5.57 (-1.75%) ▼|MA571.41+0.31 (+0.05%) ▲|MCD272.64+4.30 (+1.60%) ▲|MDLZ62.53+0.45 (+0.72%) ▲|MDT85.59-0.61 (-0.71%) ▼|META582.87-5.07 (-0.86%) ▼|MMM182.79+1.34 (+0.74%) ▲|MO68.15+0.08 (+0.11%) ▲|MRK128.69+0.69 (+0.54%) ▲|MS219.17+2.13 (+0.98%) ▲|MSFT489.21-3.60 (-0.73%) ▼|MU918.35+25.68 (+2.88%) ▲|NEE85.84-1.36 (-1.56%) ▼|NFLX73.46-0.11 (-0.15%) ▼|NKE42.03+0.50 (+1.21%) ▲|NOW116.90-1.25 (-1.05%) ▼|NVDA221.60+9.66 (+4.56%) ▲|ORCL144.20-1.54 (-1.06%) ▼|PEP138.62-0.48 (-0.35%) ▼|PFE25.55+0.14 (+0.55%) ▲|PG146.69-1.32 (-0.89%) ▼|PLTR159.42-3.24 (-1.99%) ▼|PM189.38+2.47 (+1.32%) ▲|QCOM157.84-4.83 (-2.97%) ▼|RTX221.68+3.75 (+1.72%) ▲|SBUX105.61+0.64 (+0.61%) ▲|SCHW108.27+1.92 (+1.81%) ▲|SO92.78-0.47 (-0.50%) ▼|SPG225.22-0.68 (-0.30%) ▼|T22.88-0.50 (-2.14%) ▼|TMO575.72+10.97 (+1.94%) ▲|TMUS172.75-4.46 (-2.52%) ▼|TSLA321.03-6.32 (-1.93%) ▼|TXN278.38-5.26 (-1.85%) ▼|UBER67.38-4.62 (-6.41%) ▼|UNH415.81+8.26 (+2.03%) ▲|UNP294.69-1.66 (-0.56%) ▼|UPS107.91-1.21 (-1.10%) ▼|USB64.42+0.19 (+0.30%) ▲|V368.86-0.73 (-0.20%) ▼|VZ45.79-1.10 (-2.34%) ▼|WFC89.26+0.87 (+0.98%) ▲|WMT111.67+0.12 (+0.11%) ▲|XOM152.18-1.78 (-1.16%) ▼|
29 C
New York
Wednesday, August 5, 2026

Tag: Nasdaq:BLTE

newssourceFORcompanyinformationcontent1releasesmarket

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNasdaq:BLTE

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers